AstraZeneca invests $2 billion in Summit Therapeutics for cancer-drug partnership

AstraZeneca announced a $2 billion investment in Summit Therapeutics, securing a potential 12% stake in the company. The partnership will focus on joint development of cancer drugs, including ivonescimab, positioning both firms to advance their oncology portfolios.

The investment comes as investors monitor upcoming FDA regulatory decisions on Summit's pipeline candidates. The collaboration marks a significant commitment by AstraZeneca to expand its presence in cancer therapeutics through strategic partnerships.